IMPACT Consortium
Immune & Microbiota Monitoring Partnership for Cellular Therapy in Children
Consortium-wide focus on allogeneic HCT, autologous HCT, CAR-T therapy, and BMT across indications.
Standardized multi-parametric spectral flow, harmonized gating templates, and high-dimensional subset profiling.
Harmonized collection, sequencing, and integrated analysis with clinical metadata.
Deep phenotyping of GVHD, immune reconstitution, infection risk, relapse, and survival outcomes.
Machine-learning prediction models and integrated biomarkers from immune, microbiome, and clinical data.
Consortium effort to integrate DC subsets, Tregs, and cytokine profiles for early prediction of GVHD risk.
Studying patterns of naïve T cell recovery and thymic output across pediatric transplant recipients.
Linking gut microbiome dynamics with immune recovery and clinical outcomes.
Identifying combined immune + microbiome signatures that correlate with relapse risk.